An acquisition means integration work is about to be scoped. Fundz scores the company against what you sell, and says why it matched.See it live →
IDEAYA Biosciences Receives Termination Notice from GSK for Collaboration Agreement
Dec 05, 2025•10 months ago
Contract Type
collaboration_agreement
San FranciscoBiotechnologyHealth Care
Description
On December 4, 2025, GSK communicated its election to terminate the Collaboration, Option and License Agreement with IDEAYA Biosciences. This termination will take effect ninety days after GSK's written notice. During the transition period, GSK will transfer the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical programs to IDEAYA. The company plans to evaluate its strategic options for these programs in 2026.
Company Information
Company
IDEAYA Biosciences
Location
San Francisco, California, United States
About
IDEAYA is an oncology-focused precision medicine company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality – an emerging class of precision medicine targets.
San FranciscoBiotechnologyHealth Care